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ABSTRACT 
 
Objective: To report on the routine clinical implementation of cell-free (cf)DNA analysis of 
maternal blood for trisomies 21, 18 and 13 contingent on the results of the first-trimester 
combined test in twin pregnancies. 
 
Methods: Screening for trisomies 21, 18 and 13 was carried out by a combination of maternal 
age, fetal nuchal translucency (NT) thickness, and serum free ß-hCG and PAPP-A at 11-13 
weeks’ gestation in 959 twin pregnancies in two UK NHS hospitals. Women in the high-risk 
group (risk >1 in 100) were offered options of invasive testing, cfDNA testing or no further 
testing and those in the intermediate-risk group (risk 1 in 101 to 1 in 2500 in the first phase of 
the study and 1 in 101 to 1 in 500 in the second phase) were offered cfDNA or no further testing. 
The trisomic status of the pregnancies was determined by prenatal or postnatal karyotyping or 
examination of the neonates. 
 
Results: In 42 (4.4%) of the 959 pregnancies there was termination, miscarriage or stillbirth 
with no known karyotype or there was loss to follow up. The 917 pregnancies with known 
trisomic status of both twins, included 6 that were discordant for trisomy 21, 4 discordant for 
trisomy 18 and 896 with no trisomies 21, 18 or 13. Following combined screening, 47 (5.1%), 
203 (22.2%) and 667 (72.7%) of the pregnancies were classified as high-risk, intermediate-risk 
and low-risk, respectively. The high-risk group included 5 (83.3%) cases of trisomy 21 and 3  
(75.0%) of trisomy 18. The cfDNA test was carried out in 224 pregnancies and results were 
provided in 214 (95.5%); this group included 6 with trisomy 21, 3 with trisomy 18 and 206 with 
no trisomies 21, 18 or 13. The cfDNA test correctly classified as screen positive all 6 cases of 
trisomy 21 and 2 of the 3 with trisomy 18 and as screen negative for each of the trisomies all 
206 unaffected pregnancies. Contingent screening, led to prenatal detection of all cases of 
trisomy 21 and 3 of 4 with trisomy 18. 
 
Conclusions: The study has demonstrated the feasibility of introducing cfDNA testing, 
contingent on the results of the first-trimester combined test for major trisomies, in a routine 
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population of twin pregnancies. 
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INTRODUCTION  
 
In singleton pregnancies screening for the major trisomies using a combination of fetal nuchal 
translucency (NT) thickness and serum β-human chorionic gonadotropin (β-hCG) and 
pregnancy-associated plasma protein A (PAPP-A) can detect about 90% of cases of trisomies 
21, 18 and 13, at false positive rate (FPR) of 5%.1,2 In twin pregnancies use of the combined 
test can achieve a similarly high detection rate (DR) for trisomy 21 as in singletons, but with a 
higher FPR of about 6%.3 A more effective method of screening for trisomy 21 is provided by 
analysis of cell-free (cf)DNA in maternal blood; a recent meta-analysis of clinical validation 
studies reported that in the combined total of 1963 cases of trisomy 21 and 223 932 non-trisomy 
21 singleton pregnancies, the weighted pooled DR and FPR were 99.7% (95% CI, 99.1-99.9%) 
and 0.04% (95% CI, 0.02-0.07%), respectively.4 In twin pregnancies, the performance 
of screening for trisomy 21 by cfDNA is encouraging but the number of cases reported is small; 
in a total of 24 cases of trisomy 21 and 1111 non-trisomy 21 cases, the DR was 100% (95% CI, 
95.2-100%) and FPR was 0.0% (95% CI, 0.0-0.003%), respectively.4 
 
In screening for the major trisomies in the general population, cfDNA testing can be used either 
as a first-line method of screening or contingent on the results of the combined test at 11-13 
weeks’ gestation. Contingent screening could potentially lead to a very high DR and very low 
invasive testing rate at a considerably lower cost than would be possible using cfDNA testing as 
a first-line method of screening based on current cfDNA testing costs.5,6 We have previously 
reported on the clinical implementation of such policy in singleton pregnancies.7,8 
 
The objective of this study is to examine the clinical implementation of cfDNA testing, contingent 
on the results of the combined test, in routine first-trimester screening for fetal trisomies in twin 
pregnancies.  
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METHODS 
 
Study design and participants  
 
This was a prospective study in women with twin pregnancies attending two national health 
service (NHS) hospitals in England (King’s College Hospital, London, and Medway Maritime 
Hospital, Kent) for routine care between October 2013 and January 2018. Implementation of 
contingent screening was approved by the National Research Ethics Committee (REC 
reference 13/LO/0885).  
 
During a routine visit at 11-13 weeks’ gestation, we recorded maternal demographic 
characteristics and medical history, measured maternal serum free ß-hCG and PAPP-A 
(DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA) and carried 
out an ultrasound scan to determine gestational age from the measurement of the fetal crown-
rump length (CRL)9 of the larger fetus, and chorionicity by examining the junction of the intertwin 
membrane with the placenta,10 to diagnose any major fetal abnormalities and measure fetal NT 
thickness. The measured NT was expressed as a difference from the expected normal mean for 
gestation (delta value).11 Similarly, the measured free ß-hCG and PAPP-A were converted into 
multiple of the median (MoM) values adjusted for maternal characteristics, gestational age and 
chorionicity.12,13  
 
The estimated risk for trisomy 21 and trisomies 18 and 13 was calculated and the highest of the 
two was considered in the stratification of the population. In the case of monochorionic twins a 
risk is given for the whole pregnancy; in dichorionic twins a risk is given for each fetus and the 
highest of the two was used for stratification. Women in the high-risk group (risk >1 in 100) were 
offered options of chorionic villous sampling (CVS), cfDNA testing or no further testing; this cut-
off was selected because it is used by the NHS for offering invasive testing. Women in the 
intermediate-risk group (risk 1 in 101 to 1 in 2500 in the first phase of the study and 1 in 101 to 1 
in 500 in the second phase) were offered cfDNA or no further testing. Women in the low-risk 
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group (risk <1 in 2500 in the first phase of the study and <1 in 500 in the second phase) were 
reassured that fetal trisomies were unlikely and no further testing was necessary.  
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Women provided written informed consent and maternal blood (20 mL) was sent via courier to 
the USA for cfDNA testing (HarmonyTM Prenatal Test, Ariosa Diagnostics, Inc., San Jose, CA). 
14,15 Digital analysis of selected regions (DANSR) by chromosome-selective sequencing or 
microarray was used to quantify chromosomes 21, 18 and 13. Risk scores for trisomy 21, 18, 
and 13 were provided as a percentage with ranges capped at >99% and <0.01%. In cases 
where the cfDNA test did not provide results the parents were offered repeat testing or to rely on 
the results of the combined test in deciding whether to have an invasive test or not. In cases 
with a high-risk result from the cfDNA test, the parents were advised to consider having invasive 
fetal karyotyping before deciding on the further management of their pregnancy.  
 
Patient characteristics, results of the investigations and pregnancy outcome were recorded in a 
database. The outcomes were divided into first, trisomy 21, 18 or 13 if the karyotype of chorionic 
villi, amniotic fluid or neonatal blood demonstrated the relevant trisomy in one or both fetuses, 
second, no trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood 
was normal or both neonates were phenotypically normal, third, no known karyotype in both 
fetuses because the pregnancies resulted in termination or embryo reduction, miscarriage or 
stillbirth and no karyotyping of fetal tissue was carried out, and fourth, outcome unknown 
because the pregnancies were lost to follow up. 
 
Statistical analysis 
 
Descriptive data were presented in median and interquartile range (IQR) for continuous 
variables and in numbers and percentages for categorical variables. Comparisons between 
outcome groups were by Mann-Whitney U-test for continuous variables and χ2-test or Fisher’s 
exact test for categorical variables.  
 
The statistical software package R version 3.3.3 (https://www.R-project.org/) was used for data 
analyses.  
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Role of the funding source 
 
The study was supported by a grant from The Fetal Medicine Foundation (UK Charity No: 
1037116). The cost of collection and analysis of the samples for the cell-free DNA test was 
covered by Ariosa Diagnostics, Inc. San Jose, CA, USA. These organizations had no role in 
study design, data collection, data analysis, data interpretation, or writing of the report. 
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RESULTS 
 
Study population 
 
During the study period, 977 women with twin pregnancies and two live fetuses at 11-13 weeks’ 
gestation were offered combined screening for trisomies; 959 (98.2%) accepted, but 42 (4.4%) 
of these were excluded from further analysis either because the pregnancies ended in 
termination, miscarriage or stillbirth with no known karyotype (n=29) or they were lost to follow 
up (n=13). 
  
Maternal and pregnancy characteristics in the 917 pregnancies with known trisomic status of 
both twins are summarized in Table 1; these included 740 (80.7%) dichorionic and 177 (19.3%) 
monochorionic twins. In the monochorionic twin pregnancies there were no trisomic fetuses. In 
the dichorionic twin pregnancies there were 10 where one fetus was normal and the co-twin was 
trisomic (6 cases of trisomy 21 and 4 of trisomy 18).  
 
On the basis of the maternal age distribution and the age-related risk for these trisomies at 12 
weeks’ gestation, the expected number of cases of trisomy 21 and trisomies 18 and 13 in our 
monochorionic twin pregnancies was 0.6 (95% CI: 0.07 – 4.87) and 0.3 (95% CI: 0.02 – 4.32) 
respectively.16,17  In the dichorionic twin pregnancies, on the assumption that the trisomic risk for 
each of the 1,480 fetuses was the same as in singleton pregnancies, the expected number of 
cases of trisomy 21 and trisomies 18 and 13 in our study population, was 6.4 (95% CI: 3.03 – 
13.54) and 3.4 (95% CI: 1.26 – 9.32) respectively, which were similar to the observed numbers 
of 6 and 4 respectively.16,17  
 
Stratification of risks and parental choices 
 
Following combined screening, 47 (5.1%), 203 (22.2%) and 667 (72.7%) of the pregnancies 
were classified as high-risk, intermediate-risk and low-risk, respectively. The high-risk group can 
be subdivided into a group with estimated risk of ≥ 1 in 30, which contained 27 (2.9%) cases, 
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and another with a risk of 1 in 31 to 1 in 100, which contained 20 (2.2%) cases. 
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In the high-risk group, 36.2% (17/47) opted for CVS (including 4 cases of trisomy 21 and 2 of 
trisomy 18), 57.4% (27/47) for cfDNA testing (including 1 case of trisomy 21 and 1 of trisomy 18) 
and 6.4% (3/47) did not want any further investigations. In the subgroup with risk of ≥ 1 in 30, 
55.6% (15/27) opted for CVS (including 4 cases of trisomy 21 and 2 of trisomy 18), 37.0% 
(10/27) for cfDNA testing (including 1 case of trisomy 21) and 7.4% (2/27) did not want any 
further investigations. In the intermediate-risk group, 91.6% (186/203) opted for cfDNA testing 
(including 1 case of trisomy 21) and 8.4% (17/203) did not want any further investigations. 
 
Results of the combined test 
 
Combined screening with estimated risk cut-off of 1 in 100 detected 83.3% (5/6) cases of 
trisomy 21 and 75% (3/4) with trisomy 18. One case of trisomy 21 had a risk of 1 in 939 and this 
was identified by cfDNA testing. In three of the six cases of trisomy 21, the parents chose to 
continue with the pregnancy and in the other three they had embryo reduction. One case of 
trisomy 18 had a risk of 1 in 3,450 and this case was identified by amniocentesis because at the 
routine 20 weeks scan the affected fetus had tetralogy of Fallot, clenched hands, strawberry 
shaped head and growth restriction. 
 
Implementation and performance of the cfDNA test 
 
In total, the cfDNA test was carried out in 224 pregnancies. These included 213 from the high- 
or intermediate-risk group that opted for cfDNA testing and 11 in the high-risk group that opted 
for CVS, but also had cfDNA testing for research; in the latter group the blood test was collected 
before invasive testing. Results from testing were provided after first sampling for 95.5% 
(214/224) of cases and the median fetal fraction was 8.5% (range 4 to 30%). The reasons for no 
result were insufficient fetal cfDNA for accurate evaluation in 7 cases and the sample did not 
meet thresholds for quality control in 3. In 7 of the 10 cases with no result, a further blood 
sample was obtained and a cfDNA result was provided in 1. In 8 of the 9 cases with no result 
from the cfDNA test the parents decided to avoid further testing and 1 chose to have 
amniocentesis. 
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The group of 215 pregnancies with a cfDNA result (214 from first sampling and 1 from second 
sampling) included 6 with trisomy 21, 3 with trisomy 18 and 206 with no trisomies 21, 18 or 13. 
The cfDNA test correctly classified as screen positive all 6 cases of trisomy 21 and 2 of the 3 
with trisomy 18 and as screen negative for each of the trisomies all 206 unaffected pregnancies. 
 
The distribution of estimated risk for trisomies by the combined test and the cfDNA test is given 
in Figure 1. 
 
Performance of contingent screening 
 
The study population of 917 pregnancies with known trisomic status of both twins included 6 
with trisomy 21, 4 with trisomy 18 and 907 with no trisomies 21, 18 or 13. Contingent screening, 
led to prenatal detection of all cases of trisomy 21 and 3 of 4 with trisomy 18 (1 case was 
classified as low risk by the combined test). 
 
Invasive tests were carried out in 33 (3.6%) of the study population. These included 18 (54.5%) 
for high-risk result from the combined test, 2 (6.1%) for positive result from the cfDNA test, 1 
(3.0%) for failed cfDNA testing, 5 (15.2%) for fetal defects detected by ultrasound examination in 
the second trimester of pregnancy, 7 (21.2%) for endoscopic laser separation of communicating 
placental vessels in association with severe twin-to-twin transfusion syndrome or selective fetal 
growth restriction and 1 (3.0%) for prenatal diagnosis of sickle cell disease.  
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DISCUSSION 
 
Main findings of the study 
 
The study has demonstrated the feasibility of introducing cfDNA testing, contingent on the 
results of the first-trimester combined test for major trisomies, in a routine population of twin 
pregnancies. The observed number of trisomies was as expected on the basis of the maternal 
age distribution of the study population.  
 
In our participating hospitals, about 98% of women attending for a routine ultrasound 
examination at 11-13 weeks’ gestation accepted the offer of screening for fetal trisomies by the 
combined test and this was successfully carried out in all cases. In the high-risk group, 36% of 
women opted for invasive testing, 57% for cfDNA testing and 6% for no further tests; in the 
subgroup with risk of ≥ 1 in 30, 56% opted for invasive testing. In the intermediate-risk group, 
92% opted for cfDNA testing and 8% for no further tests. These results on patient choices are 
very similar to those reported in our previous study for singleton pregnancies.8 In the high-risk 
group the choice between CVS and cfDNA testing was influenced by objective evidence derived 
from the patient-specific risk obtained from the combined test. In 3 of the 6 cases of trisomy 21 
the parents chose to continue with the pregnancy and in the other 3 they had embryo reduction; 
there were no obvious differences between the two groups in terms of maternal age, race, parity 
or method of conception. 
 
The combined test, at risk cut-off of 1 in 100, could have potentially identified 5 of 6 cases of 
trisomy 21 and 3 of 4 of trisomy 18, at FPR of 4.3%; the number of affected cases is too small 
for accurate assessment of the performance of screening, but the results are consisted with the 
modelled performance of about 90% detection of the major trisomies at FPR of 6%.3  
 
In the group undergoing cfDNA testing, results were provided for 96% of pregnancies; the 
failure rate in twin pregnancies was twice as high as that in our previous study for singleton 
pregnancies.8 The cfDNA test detected all cases of trisomy 21 and 2 of 3 with trisomy 18 in the 
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population having this test, at FPR of 0%. As in the case of the combined test, the number of 
affected cases is too small for accurate assessment of the performance of cfDNA screening, but 
the results are consisted with those of previous reports.18-25 
 
Limitations of the study 
 
The main limitation of the study relates to the small number of trisomic pregnancies and the 
small number of cases which actually had cfDNA testing, preventing definitive conclusions to be 
drawn in terms of performance of screening by these two methods. 
 
The results on the uptake of various options of screening and management of affected 
pregnancies depending on risk categories defined by the combined test highlight some general 
principles concerning the factors that influence patient decisions. However, the exact rates of 
uptake of a specific option may not be generalizable to all populations from different racial and 
socioeconomic backgrounds in different countries and healthcare systems. 
 
Previous studies of cfDNA testing in twin pregnancies 
 
There are only seven prospective studies with complete follow-up reporting on the performance 
of cfDNA testing in twin pregnancies.19-25 Two studies examined a routine population,24,25 three 
examined pregnancies at high-risk of aneuploidies,21-23 and two were in a mixed population of 
high and low-risk pregnancies19,20. In the combined total of 31 cases of trisomy 21 and 2,008 
non-trisomic pregnancies the detection rate was 100% and false positive rate was 0.05%. 
Although the number of twin pregnancies examined by cfDNA testing is considerably lower than 
singleton pregnancies,4 the results suggest the test is equally effective in identifying trisomy 21.  
 
Conclusions 
 
Clinical implementation of cfDNA testing contingent on the results from a previously performed 
first-trimester combined test is feasible and it could potentially lead to the prenatal detection of a 
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higher proportion of affected pregnancies and a lower invasive-testing rate than in screening by 
the combined test alone. However, in clinical practice, prenatal detection of trisomies and 
pregnancy outcome depend not only on performance of screening tests but also on parental 
choices. Consequently, clinical implementation of cfDNA testing contingent on the results of the 
combined test may only have a modest impact in reducing the rate of invasive testing and a 
small effect on the rate of live births with trisomy 21. 
 
 
Acknowledgement: This study was supported by a grant from the Fetal Medicine Foundation 
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Figure legend: 
 
Figure 1 The distribution of estimated risk for trisomies by the combined test and the cfDNA 
test.
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Table 1. Characteristics of the study population. 
 
 
Comparisons between the high- and intermediate-risk groups was made to the low-risk group by Mann 
Whitney-U test for continuous variables and by Chi-square or Fisher exact test for categorical variables, 
with post-hoc Bonferroni correction with adjusted P-value of <0.025 (*). IQR = interquartile range. 
 
Characteristics High-risk (n=47) 
Intermediate-risk 
(n=203) 
Low-risk 
(n=667) 
Maternal age in years, median (IQR) 36.2 (32.5-40.0)* 36.6 (33.3-38.9)* 32.0 (28.3-35.5) 
Maternal body mass index in kg/m2, median (IQR) 26.9 (22.1-30.5) 25.0 (22.6-28.1) 25.4 (22.3-30.0) 
Racial origin    
   White, n (%) 33 (70.2) 153 (75.4) 512 (76.8) 
   Black, n (%) 12 (25.5) 32 (15.7) 105 (15.7) 
   South Asian, n (%) 2 (4.3) 12 (5.9) 25 (3.7) 
   East Asian, n (%) - 3 (1.5) 5 (0.7) 
   Mixed, n (%) - 3 (1.5) 21 (3.1) 
Cigarette smoker, n (%)ew  1 (2.1) 3 (1.5) 34 (5.1) 
Parity    
   Nulliparous, n (%) 25 (53.2) 87 (42.9) 272 (40.8) 
   Parous, n (%) 22 (46.8) 116 (57.1) 395 (59.2) 
Method of conception    
   Spontaneous, n (%) 31 (66.0) 129 (63.5) 479 (71.8) 
   Assisted conception, n (%) 16 (34.0) 74 (36.5) 188 (28.2) 
Estimated risk for trisomies 21 or 18/13 (1 in ), median (IQR) 24 (57-5)* 463 (1,182 -276)* 3,833 (7,321-1,952) 
Patient choice for further testing    
   Cell-free DNA test, n (%) 27 (57.4) 186 (91.6) - 
   Chorionic villous sampling, n (%) 17 (36.2) - - 
   Nothing, n (%) 3 (6.4)* 17 (8.4)* 667 (100%) 
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